France’s leading Female Bio-entrepreneur joins board of Abivax

17/09/2015 - 2 minutes

Dominique Costantini is one of France’s leading biotech figures, with over 20 years experience on boards, partnerships and business backing in some of the biotech industries leading brands.

With a medical background specializing in immunology (from Paris V University), Costantini co-founded oncology focused Onxeo in 1997. Formerly known as BioAlliance Pharma, this biotech went public under Costantini’s guidance which in 2005 secured an IPO total of €100M. BioAlliance Pharma is in fact the only French biotech ever to have 2 FDA-approved drugs on the market – an impressive testament to Costantini’s work.

Costantini remained CEO of BioAlliance Pharma up until 2011, then moving on to co-found OSE Pharma, which has had recent success in its phase II trials for Tedopi (developed as a T-cell therapy for non-small cell lung cancer). Romain (blogger at Labiotech) interviewed Costantini on her position at OSE Pharma at the end of March this year.

Her new position at Abivax will join Philippe Pouletty (Chairman of the board) as part of an international management team,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following: